0T6G.LSE Q32 Bio Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -31.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0T6G.LSE undervalued?
Graham numberThe Graham number of Q32 Bio Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Q32 Bio Inc. fundamental analysis
No fundamental analysis for Q32 Bio Inc. yet.
Q32 Bio Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling me…
Full company profileQ32 Bio Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Q32 Bio Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 5.32M | 1.67M | 2.70M | 34.0M | 3.21M | -6.65M | - | 53.7M | - |
| Gross Profit | -240K | -684K | -42.6M | -87.7M | -97.7M | 24.4M | 609K | -38.4M | -487K | 53.3M | -350K |
| Operating Income | -10.0M | -29.7M | -59.9M | -110M | -130M | -95.9M | -133M | -48.3M | -66.1M | 16.9M | -33.7M |
| EBITDA | -7.81M | -29.3M | -58.6M | -97.6M | -120M | -86.2M | 3.80M | -47.8M | -45.3M | 17.3M | -33.3M |
| Net Income | -8.05M | -30.0M | -55.6M | -104M | -129M | -95.8M | -5.01M | -53.7M | -47.7M | 29.8M | -33.1M |
| EPS | -3.87 | -14 | -1.49 | -2.36 | -2.76 | -31 | -1.57 | -17 | -4.94 | 2.42 | -1.63 |
| Balance Sheet | |||||||||||
| Total Assets | 14.2M | 138M | 259M | 311M | 264M | 212M | 228M | 47.1M | 92.3M | 61.8M | 116M |
| Total Liabilities | 6.72M | 39.2M | 62.7M | 52.1M | 67.7M | 42.1M | 50.5M | 119M | 86.7M | 19.8M | 9.96M |
| Shareholders' Equity | 7.50M | 98.3M | 196M | 259M | 196M | 170M | 178M | 73.0M | 5.68M | 42.0M | 106M |
| Cash & Short-term Investments | 11.4M | 130M | 215M | 262M | 217M | 156M | 43.9M | 25.6M | 78.0M | 48.3M | 106M |
| Total Debt | - | - | - | - | 15.4M | 23.9M | 44.7M | 50.8M | 18.9M | 15.3M | 5.30M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.48M | 6.48M | -42.6M | -91.4M | -94.3M | -110M | -114M | -18.7M | -67.7M | -33.5M | -18.8M |
| Capital Expenditure | 1.99M | 1.96M | 24.9M | 21.8M | 3.73M | 2.40M | 1.29M | 5.00K | 75.0K | 0.00 | 0.00 |
| Free Cash Flow | -10.5M | 4.52M | -67.5M | -113M | -98.1M | -112M | -115M | -18.7M | -67.8M | -33.5M | -18.8M |
| Ratios | |||||||||||
| ROE | -107.3% | -30.5% | -28.3% | -40.2% | -65.7% | -56.4% | -2.8% | -73.6% | -841.1% | 71.0% | -31.3% |
| ROA | -56.6% | -21.8% | -21.5% | -33.5% | -48.8% | -45.2% | -2.2% | -114.2% | -51.7% | 48.3% | -28.6% |
| Net Profit Margin | - | - | -1,044.3% | -6,237.5% | -4,762.9% | -281.9% | -156.0% | - | - | 55.5% | - |
| Debt to Equity | - | - | - | - | 0.08x | 0.14x | 0.25x | 0.70x | 3.33x | 0.37x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Q32 Bio Inc. dividends
Q32 Bio Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.055556:1 on Mar 26, 2024.
Who owns Q32 Bio Inc.
- Insiders 2.08%
- Institutions 95.16%
- Public & others 2.77%
- Free float 12.7M
Q32 Bio Inc. company profile
- Company name
- Q32 Bio Inc.
- Ticker
- 0T6G.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- 830 Winter Street, Waltham, MA, United States, 02451
- Phone
- 781 999 0232
- Website
- q32bio.com
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Q32 Bio Inc. management
7- Ms. Jodie Pope MorrisonCEO & Director · born 1976
- Mr. Lee H. Kalowski M.B.A.CFO & President · born 1981
- Dr. Shelia M. Violette Ph.D.Co-founder, Chief Scientific Officer & President of Research · born 1961
- Mr. David Appugliese J.D.Senior VP & Head of People
- Ms. Maria Marzilli M.P.H.Chief Business Officer
- Dr. José M. Trevejo M.D., Ph.D.Chief Medical Officer · born 1972
- Dr. Elham Hershberger Pharm.D.Chief Development Officer · born 1968